Q1 Earnings Estimate for CalciMedica Issued By HC Wainwright

CalciMedica Inc. (NASDAQ:CALC) – Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of CalciMedica in a report released on Tuesday, March 3rd. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.31) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for CalciMedica’s Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.43) EPS, FY2026 earnings at ($1.45) EPS, FY2027 earnings at ($0.86) EPS and FY2028 earnings at ($0.98) EPS.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter.

Several other equities analysts also recently commented on CALC. Wall Street Zen raised CalciMedica to a “sell” rating in a research note on Saturday, January 17th. Oppenheimer dropped their price objective on CalciMedica from $20.00 to $10.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CalciMedica in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $13.00.

CalciMedica Trading Up 5.9%

CALC stock opened at $0.66 on Friday. CalciMedica has a 1-year low of $0.46 and a 1-year high of $7.20. The company has a current ratio of 3.58, a quick ratio of 4.04 and a debt-to-equity ratio of 1.39. The business’s 50 day moving average is $2.97 and its 200-day moving average is $3.34. The firm has a market cap of $10.40 million, a P/E ratio of -0.41 and a beta of 0.60.

Institutional Trading of CalciMedica

Hedge funds and other institutional investors have recently made changes to their positions in the business. Boothbay Fund Management LLC acquired a new position in CalciMedica during the 4th quarter worth about $506,000. Stonehage Fleming Financial Services Holdings Ltd bought a new position in shares of CalciMedica in the third quarter worth about $165,000. Sheets Smith Investment Management acquired a new position in shares of CalciMedica during the third quarter worth approximately $157,000. PVG Asset Management Corp acquired a new position in shares of CalciMedica during the fourth quarter worth approximately $302,000. Finally, Envestnet Asset Management Inc. grew its stake in shares of CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the last quarter.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.